Structure-Based Discovery of SIAIS001 as an Oral Bioavailability ALK Degrader Constructed from Alectinib

Discovery of a PROTAC targeting ALK with in vivo activity

(2021) Guoyi Yan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition

(2020) DONGCHAN KIM et al.   ANTICANCER RESEARCH

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance

(2020) Ning Sun et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction

(2019) Xing Qiu et al.   ORGANIC LETTERS

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

(2019) Longchuan Bai et al.   CANCER CELL

Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)

(2018) Chengwei Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

(2018) Chelsea E. Powell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

(2018) Chong Qin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Plasticity in binding confers selectivity in ligand-induced protein degradation

(2018) Radosław P. Nowak et al.   Nature Chemical Biology

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

(2018) Satoshi Yoda et al.   Cancer Discovery

Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)

(2018) Chung Hyo Kang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

(2018) Yangbing Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib

(2016) E. Larkins et al.   CLINICAL CANCER RESEARCH

Catalytic in vivo protein knockdown by small-molecule PROTACs

(2015) Daniel P Bondeson et al.   Nature Chemical Biology

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers

(2011) T. Sasaki et al.   CLINICAL CANCER RESEARCH

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA